TNYA
Tenaya Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 1
consensus rating "Strong Buy"
ample liquidity
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About TNYA
Tenaya Therapeutics, Inc.
A clinical-stage biotech company that develops gene therapies for rare genetic disorders
Biological Technology
Invalid Date
07/30/2021
NASDAQ Stock Exchange
97
12-31
Common stock
171 Oyster Point Boulevard, 5th Floor, South San Francisco, CA 94080
--
Tenaya Therapeutics, Inc., was incorporated in Delaware in August 2016. The company is a preclinical stage biotechnology company focused on discovering, developing and delivering treatments for the underlying drivers of heart disease. The company is advancing product candidates from three distinct but interrelated product platforms: gene therapy, cell regeneration and precision medicine.
Company Financials
EPS
TNYA has released its 2025 Q1 earnings. EPS was reported at -0.24, versus the expected -0.20, missing expectations. The chart below visualizes how TNYA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
